Glucagon-Like Peptide-1 (GLP-1) Receptors Expressed on Nerve Terminals in the Portal Vein Mediate the Effects of Endogenous GLP-1 on Glucose Tolerance in Rats
The DOI matches its Crossref record; 51 of the 57 references it cites were found in a registry or an index.
Abstract
Glucagon-like peptide-1 (GLP-1) is an intestinal hormone that is secreted during meal absorption and is essential for normal glucose homeostasis. However, the relatively low plasma levels and rapid metabolism of GLP-1 raise questions as to whether direct endocrine action on target organs, such as islet cells, account for all of its effects on glucose tolerance. Recently, an alternative neural pathway initiated by sensors in the hepatic portal region has been proposed to mediate GLP-1 activity. We hypothesized that visceral afferent neurons in the portal bed express the GLP-1 receptor (GLP-1r) and regulate glucose tolerance. Consistent with this hypothesis, GLP-1r mRNA was present in the nodose ganglia, and nerve terminals innervating the portal vein contained the GLP-1r. Rats given an intraportal infusion of the GLP-1r antagonist, [des-His(1),Glu(9)] exendin-4, in a low dose, had glucose intolerance, with a 53% higher glucose excursion compared with a vehicle-infused control group. Infusion of [des-His(1),Glu(9)] exendin-4 at an identical rate into the jugular vein had no effect on glucose tolerance, demonstrating that this dose of GLP-1r antagonist did not affect blood glucose due to spillover into the systemic circulation. These studies demonstrate that GLP-1r are present on nerve terminals in the hepatic portal bed and that GLP-1 antagonism localized to this region impairs glucose tolerance. These data are consistent with an important component of neural mediation of GLP-1 action.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“GLP-1 receptor was found in nerves that innervate hepatocytes [172], but their presence on human liver or hepatocytes is debated as found by some [169,170] but not others [173,174].”
From Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH (2020) · cites this paper as [172]
Citations
Cites
MENTLEIN, R., GALLWITZ, B., & SCHMIDT, W. E. (1993) · European Journal of Biochemistry · doi:10.1111/j.1432-1033.1993.tb17986.x · Cited by 1,161
Kieffer, T. J., McIntosh, C. H., & Pederson, R. A. (1995) · Endocrinology · doi:10.1210/endo.136.8.7628397 · Cited by 1,124
Nauck, M. A., Kleine, N., �rskov, C., Holst, J. J., Willms, B., & Creutzfeldt, W. (1993) · Diabetologia · doi:10.1007/bf00401145 · Cited by 1,092
Kieffer, T. J., & Francis Habener, J. (1999) · Endocrine Reviews · doi:10.1210/edrv.20.6.0385 · Cited by 1,062
Thorens, B. (1992) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.89.18.8641 · Cited by 906
Vilsbøll, T., Krarup, T., Deacon, C. F., Madsbad, S., & Holst, J. J. (2001) · Diabetes · doi:10.2337/diabetes.50.3.609 · Cited by 884
Deacon, C. F., Nauck, M. A., Toft-Nielsen, M., Pridal, L., Willms, B., & Holst, J. J. (1995) · Diabetes · doi:10.2337/diab.44.9.1126 · Cited by 878
Hansen, L., Deacon, C. F., Ørskov, C., & Holst, J. J. (1999) · Endocrinology · doi:10.1210/endo.140.11.7143 · Cited by 595
Enhancing Incretin Action for the Treatment of Type 2 Diabetes
Drucker, D. J. (2003) · Diabetes Care · doi:10.2337/diacare.26.10.2929 · Cited by 579
Nauck, M. A. (1993) · Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.76.4.912 · Cited by 506
Cited by
Items 101–200 of 315
Liu, W. J., Jin, H. Y., Lee, K. A., Xie, S. H., Baek, H. S., & Park, T. S. (2011) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01272.x · Cited by 84
“Previous studies demonstrated that the GLP-1 receptor was found in peripheral neurons of male rats and in the epidermis or hair follicles of newborn mice (Nakagawa et al., 2004; List et al., 2006; Vahl et al., 2007).”
ResultPabreja, K., Mohd, M. A., Koole, C., Wootten, D., & Furness, S. G. B. (2014) · British Journal of Pharmacology · doi:10.1111/bph.12313 · Cited by 84
“Vahl et al. (Vahl et al., 2007) use immunocytochemistry to demonstrate GLP-1R expression in hepatic portal vein nerve terminals; however, it must be noted that the antibody used is no longer available from AbCam, and the replacement does not recognize the GLP-1R (Panjwani et al., 2013).”
BackgroundInfluentialObesity surgery and gut–brain communication
Berthoud, H.-R., Shin, A. C., & Zheng, H. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.01.023 · Cited by 83
Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives
Jin, T., & Weng, J. (2016) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00069.2016 · Cited by 83
“It is necessary to point out that a number of studies have suggested an alternative model of postprandial GLP-1 action via the neural circuit involving the hepatic portal region (2, 4, 48, 65, 71, 100).”
BackgroundMeirelles, K., Ahmed, T., Culnan, D. M., Lynch, C. J., Lang, C. H., & Cooney, R. N. (2009) · Annals of Surgery · doi:10.1097/sla.0b013e3181904af0 · Cited by 81
“This observation has raised concerns regarding the importance of portal GLP-1 concentrations in regulating glucose homeostasis and represents a potential limitation of the current study which only measured systemic incretin levels.(50) Normally, GIP and GLP-1 induce -cell proliferation, inhibit apoptosis, and stimulat…”
BackgroundResultThe effects of dual GLP-1/GIP receptor agonism on glucagon secretion-A Review
Mathiesen, D. S., Bagger, J. I., Bergmann, N. C., Lund, A., Christensen, M. B., Vilsbøll, T., & Knop, F. K. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20174092 · Cited by 80
Regulation of body weight: Lessons learned from bariatric surgery
Albaugh, V. L., He, Y., Münzberg, H., Morrison, C. D., Yu, S., & Berthoud, H. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101517 · Cited by 83
“[213] Vahl TP, Tauchi M, Durler TS, Elfers EE, Fernandes TM, Bitner RD, et al.”
BackgroundGLP‐1R and amylin agonism in metabolic disease: complementary mechanisms and future opportunities
Roth, J. D., Erickson, M. R., Chen, S., & Parkes, D. G. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2011.01537.x · Cited by 74
Neuronal and intracellular signaling pathways mediating GLP-1 energy balance and glycemic effects
Hayes, M. R. (2012) · Physiology & Behavior · doi:10.1016/j.physbeh.2012.02.017 · Cited by 74
“A conservative interpretation of these findings together with a previous report examining GLP-1 signaling in the hepatoportal bed [7], would be to conclude that while GLP-1R expressed within the hepatoportal region can mediate GLP-1-induced incretin signaling, CHB GLP-1R are not required for endogenous GLP-1-mediated…”
Woerle, H. J., Carneiro, L., Derani, A., Göke, B., & Schirra, J. (2012) · Diabetes · doi:10.2337/db11-1701 · Cited by 73
“Plasma glucagon concentration in response to hyperglycemic isoglycemic clamp experiments with intravenous (IV) saline plus duodenal meal (blue triangles) or exendin(9-39) (ex[9-39]) IV plus duodenal meal (yellow squares) and isoglycemic IV glucose experiments without intraduodenal meal perfusion (red circles) in HS (A…”
InfluentialThe role of the vagus nerve in appetite control: Implications for the pathogenesis of obesity
Cork, S. C. (2018) · Journal of Neuroendocrinology · doi:10.1111/jne.12643 · Cited by 77
Cummings, B. P., Stanhope, K. L., Graham, J. L., Baskin, D. G., Griffen, S. C., Nilsson, C., Sams, A., Knudsen, L. B., Raun, K., & Havel, P. J. (2010) · Diabetes · doi:10.2337/db09-1564 · Cited by 72
“There is increasing evidence that GLP-1 may act to enhance peripheral insulin sensitivity and reduce hepatic gluconeogenesis independent of its effects on pancreatic hormones (35), which may be mediated by portal GLP-1 receptors that signal to the CNS through vagal afferent nerves and autonomic efferent signals to ins…”
BackgroundBifari, F., Manfrini, R., Dei Cas, M., Berra, C., Siano, M., Zuin, M., Paroni, R., & Folli, F. (2018) · Pharmacological Research · doi:10.1016/j.phrs.2018.09.025 · Cited by 69
Imai, J., & Katagiri, H. (2021) · International Immunology · doi:10.1093/intimm/dxab023 · Cited by 80
Sensing Via Intestinal Sweet Taste Pathways
Young, R. L. (2011) · Frontiers in Neuroscience · doi:10.3389/fnins.2011.00023 · Cited by 69
Gut-pancreas-liver Axis as a target for treatment of NAFLD/NASH
Svegliati-Baroni, G., Patrício, B., Lioci, G., Macedo, M. P., & Gastaldelli, A. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21165820 · Cited by 66
Vagal mediation of GLP-1's effects on food intake and glycemia
Krieger, J.-P., Langhans, W., & Lee, S. J. (2015) · Physiology & Behavior · doi:10.1016/j.physbeh.2015.06.001 · Cited by 67
Liu, S., Wu, D., Quan, Y., Kamiyama, F., Kusamori, K., Katsumi, H., Sakane, T., & Yamamoto, A. (2015) · Molecular Pharmaceutics · doi:10.1021/acs.molpharmaceut.5b00765 · Cited by 68
Intestinal glucose metabolism revisited
Mithieux, G., & Gautier‐Stein, A. (2014) · Diabetes Research and Clinical Practice · doi:10.1016/j.diabres.2014.04.008 · Cited by 79
“Accordingly, the improvement of glucose control by GLP-1 is attenuated upon antagonizing the GLP-1 receptor in the portal vein [6].”
BackgroundInfluentialCombination of Obesity and High-Fat Feeding Diminishes Sensitivity to GLP-1R Agonist Exendin-4
Duca, F. A., Sakar, Y., & Covasa, M. (2013) · Diabetes · doi:10.2337/db12-1204 · Cited by 64
“Reduced vagal responsiveness to Ex-4 in OP rats may also be due to dysregulation between GLP-1 and leptin signaling, because vagal afferents contain leptin and GLP-1 receptors (5,16) and leptin enhances the response to GLP-1 (17).”
BackgroundCNS GLP-1 regulation of peripheral glucose homeostasis
Sandoval, D. A. (2008) · Physiology & Behavior · doi:10.1016/j.physbeh.2008.04.018 · Cited by 64
“Hepatic expression of GLP-1r is low [86,87] if any [88,89] but GLP-1r are expressed on nodose ganglion nerves [90,91] and GLP-1r protein is located on nerve terminals within the portal vein region [91].”
Peripheral Glucagon-like Peptide-1 (GLP-1) and Satiation
Punjabi, M., Arnold, M., Geary, N., Langhans, W., & Pacheco‐López, G. (2011) · Physiology & Behavior · doi:10.1016/j.physbeh.2011.02.038 · Cited by 75
PPARγ in Vagal Neurons Regulates High-Fat Diet Induced Thermogenesis
Liu, C., Bookout, A. L., Lee, S., Sun, K., Jia, L., Lee, C., Udit, S., Deng, Y., Scherer, P. E., Mangelsdorf, D. J., et al. (2014) · Cell Metabolism · doi:10.1016/j.cmet.2014.01.021 · Cited by 61
“Moreover, there is emerging evidence that many antidiabetic and antiobesity agents directly act on vagal afferents, including agonists for the glucagon-like peptide 1 receptor and cannabinoid 1 receptor (Burdyga et al., 2004; Vahl et al., 2007).”
Pérez-Tilve, D., González-Matías, L., Aulinger, B. A., Alvarez-Crespo, M., Gil-Lozano, M., Alvarez, E., Andrade-Olivie, A. M., Tschöp, M. H., D'Alessio, D. A., & Mallo, F. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00464.2009 · Cited by 61
Self-citationDalle, S., Burcelin, R., & Gourdy, P. (2013) · Cellular Signalling · doi:10.1016/j.cellsig.2012.11.009 · Cited by 60
Ren, W., Chen, J., Wang, W., Li, Q., Yin, X., Zhuang, G., Zhou, H., & Zeng, W. (2024) · Neuron · doi:10.1016/j.neuron.2023.12.012 · Cited by 68
The GLP-1 agonist, liraglutide, as a pharmacotherapy for obesity
Crane, J., & McGowan, B. (2016) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622315620180 · Cited by 59
Plamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Wettergren, A., Svendsen, L. B., Meisner, S., Hovendal, C., Knop, F. K., Vilsbøll, T., et al. (2013) · European Journal of Endocrinology · doi:10.1530/eje-13-0264 · Cited by 58
Wu, T., Rayner, C. K., & Horowitz, M. (2015) · Handbook of experimental pharmacology · doi:10.1007/164_2015_9 · Cited by 68
Raab, E. L., Vuguin, P. M., Stoffers, D. A., & Simmons, R. A. (2009) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00519.2009 · Cited by 57
“It is also possible that Ex-4 is mediating its actions in the IUGR neonate through GLP-1 receptors in the portal vein, as a number of investigators have shown that Ex-4 can reduce glucose, independent of islet hormones or gastric emptying (3, 4, 9, 28, 38, 39, 41, 57).”
BackgroundDuca, F. A., Bauer, P. V., Hamr, S. C., & Lam, T. K. T. (2015) · Cell Metabolism · doi:10.1016/j.cmet.2015.07.003 · Cited by 64
“Similarly, portal infusion of exendin-9 impairs glucose tolerance in a pseudo-fasting-refeeding paradigm where fasted rats are anaesthetized and given a gastric bolus of glucose (Vahl et al., 2007).”
Resveratrol Modulates the Gut-Brain Axis: Focus on Glucagon-Like Peptide-1, 5-HT, and Gut Microbiota
Chung, J. Y., Jeong, J., & Song, J. (2020) · Frontiers in Aging Neuroscience · doi:10.3389/fnagi.2020.588044 · Cited by 60
Gu, W., Winters, K. A., Motani, A. S., Komorowski, R., Zhang, Y., Liu, Q., Wu, X., Rulifson, I. C., Sivits, G., Graham, M., et al. (2010) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00102.2010 · Cited by 54
“The extrapancreatic actions of GLP-1 include inhibition of gastric emptying, regulation of appetite and satiety, suppression of glucose production, and promotion of hepatic glucose uptake (2, 4, 20, 23, 25, 27).”
BackgroundBrain GLP-1 and insulin sensitivity
Sandoval, D. A., & Sisley, S. R. (2015) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2015.02.017 · Cited by 58
Khound, R., Taher, J., Baker, C., Adeli, K., & Su, Q. (2017) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.117.310251 · Cited by 51
The Role of Glucagon-Like Peptide-1 in Energy Homeostasis
Salehi, M., & Purnell, J. Q. (2019) · Metabolic Syndrome and Related Disorders · doi:10.1089/met.2018.0088 · Cited by 46
Insight into the role of DPP-4 in fibrotic wound healing
Zhang, K., Liu, S., Jia, Y., Zou, M., Teng, Y., Chen, Z.-H., Li, Y., Guo, D., Wu, J., Yuan, Z., et al. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113143 · Cited by 52
Salehi, M., Woods, S. C., & D'Alessio, D. A. (2015) · Obesity · doi:10.1002/oby.21186 · Cited by 48
“Therefore, these findings may not apply to GB where large amounts of GLP-1 are secreted into the portal vein after eating, causing an exaggerated discrepancy between portal and peripheral levels (33), and potentially activating portal GLP-1 sensors (34).”
BackgroundSelf-citationJessen, L., Smith, E. P., Ulrich-Lai, Y., Herman, J. P., Seeley, R. J., Sandoval, D., & D’Alessio, D. (2017) · Endocrinology · doi:10.1210/en.2016-1826 · Cited by 48
Self-citationNutrition and l and K-enteroendocrine cells
Gutierrez-Aguilar, R., & Woods, S. C. (2011) · Current Opinion in Endocrinology, Diabetes & Obesity · doi:10.1097/med.0b013e32834190b5 · Cited by 47
Self-citationA role for the gut-to-brain GLP-1-dependent axis in the control of metabolism
Burcelin, R., Sérino, M., & Cabou, C. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.09.003 · Cited by 52
Wang, Y., Zhou, Y., Wang, Z., Ni, Y., Prud’homme, G. J., & WANG, Q. (2025) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/clinem/dgaf336 · Cited by 64
Nutrient sensing in the gastrointestinal tract: Possible role for nutrient transporters
Raybould, H. E. (2008) · Journal of Physiology and Biochemistry · doi:10.1007/bf03174091 · Cited by 53
“The cell bodies of vagal afferents express GLP-1 receptors and these terminate in the hepatic portal vein and infusion of low doses of GLP-1 receptor antagonist into the portal vein induced glucose intolerance in rats (40).”
BackgroundJohnson, K. M. S., Edgerton, D. S., Rodewald, T., Scott, M., Farmer, B., Neal, D., & Cherrington, A. D. (2007) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00275.2007 · Cited by 46
Ghrelin, the proglucagon-derived peptides and peptide YY in nutrient homeostasis
Dong, C. X., & Brubaker, P. L. (2012) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/nrgastro.2012.185 · Cited by 51
Incretin-Based Therapy for Prevention of Diabetic Vascular Complications
Mima, A. (2015) · Journal of Diabetes Research · doi:10.1155/2016/1379274 · Cited by 48
“In spite of C-reactive protein (CRP) levels in patients with recent-onset type 1 diabetes being the same as those measured in the control group, elevated CRP levels have been observed in long-term type 1 diabetes patients [15].”
BackgroundZheng, D., Ionut, V., Mooradian, V., Stefanovski, D., & Bergman, R. N. (2009) · Diabetes · doi:10.2337/db08-0875 · Cited by 43
“The existence of such a GLP-1 sensing mechanism has been suggested by anatomical and functional studies, showing GLP-1 receptors expressed on nerve terminals in portal vein (21) and increased vagal discharge rate by intraportal GLP-1 infusion (20).”
BackgroundPeripheral neural targets in obesity
Page, A. J., Symonds, E., Peiris, M., Blackshaw, L. A., & Young, R. L. (2012) · British Journal of Pharmacology · doi:10.1111/j.1476-5381.2012.01951.x · Cited by 43
“In support of a paracrine action of enteroendocrine cells, subsets of intestinal vagal afferents are known to express receptors for a number of key hormones released by gut epithelial cells, including those released in response to luminal nutrients (Kakei et al., 2002; Raybould et al., 2003; Nakagawa et al., 2004; Vah…”
BackgroundCentral nervous system regulation of hepatic lipid and lipoprotein metabolism
Taher, J., Farr, S., & Adeli, K. (2016) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000373 · Cited by 56
Ability of GLP-1 to decrease food intake is dependent on nutritional status
Ronveaux, C. C., de Lartigue, G., & Raybould, H. E. (2014) · Physiology & Behavior · doi:10.1016/j.physbeh.2014.06.015 · Cited by 41
Fujiwara, K., Gotoh, K., Chiba, S., Masaki, T., Katsuragi, I., Kakuma, T., & Yoshimatsu, H. (2012) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2011.07563.x · Cited by 41
Pharmacokinetic and Pharmacodynamic Modeling of Exendin-4 in Type 2 Diabetic Goto-Kakizaki Rats
Gao, W., & Jusko, W. J. (2010) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1124/jpet.110.175752 · Cited by 41
“Acute administration of exendin-4 has been shown to ameliorate hyperglycemia in animals by stimulating insulin secretion or directly promoting glucose metabolism (Vahl et al., 2007; Sandoval et al., 2008; Zheng et al., 2009).”
BackgroundPleiotropic Actions of the Incretin Hormones
McIntosh, C. H. S., Widenmaier, S. B., & Kim, S. (2010) · Vitamins and hormones · doi:10.1016/b978-0-12-381517-0.00002-3 · Cited by 46
CNS Control of Glucose Metabolism: Response to Environmental Challenges
Arble, D. M., & Sandoval, D. A. (2013) · Frontiers in Neuroscience · doi:10.3389/fnins.2013.00020 · Cited by 48
“However, GLP-1 receptors are located on afferent neurons that innervate the hepatic portal vein (Vahl et al., 2007) and on enteric neurons within the gastrointestinal tract (Amato et al., 2010).”
BackgroundGlucagon-like peptide-1 inhibits voltage-gated potassium currents in mouse nodose ganglion neurons
gaisano, G. G., j. park, S., daly, D. M., & beyak, M. J. (2010) · Neurogastroenterology & Motility · doi:10.1111/j.1365-2982.2009.01430.x · Cited by 40
GLP-1: benefits beyond pancreas
Muscogiuri, G., Cignarelli, A., Giorgino, F., Prodram, F., Santi, D., Tirabassi, G., Balercia, G., Modica, R., Faggiano, A., & Colao, A. (2014) · Journal of Endocrinological Investigation · doi:10.1007/s40618-014-0137-y · Cited by 42
“identified [30]; in fact, several experiments conducted in vagotomised animals showed no reduction in food intake”
Hepatic nervous system and neurobiology of the liver
Jensen, K. J., Alpini, G., & Glaser, S. (2013) · Comprehensive physiology · doi:10.1002/j.2040-4603.2013.tb00506.x · Cited by 38
“nerves in the portal vein via GLP-1 receptors (98).”
Parabrachial Nucleus Contributions to Glucagon-Like Peptide-1 Receptor Agonist-Induced Hypophagia
Swick, J., Alhadeff, A. L., Grill, H. J., Urrea, P., Lee, S. M., Roh, H., & Baird, J.-P. (2015) · Neuropsychopharmacology · doi:10.1038/npp.2015.50 · Cited by 37
Hoffman, S., ALVARES, D. C. L., & Adeli, K. (2022) · Molecular Metabolism · doi:10.1016/j.molmet.2022.101590 · Cited by 47
“T antagonist into the portal vein but not the jugular vein was able to impair glucose tolerance in rats [13].”
BackgroundThe effects of GLP-1 infusion in the hepatic portal region on food intake
Kim, D.-H., D'Alessio, D. A., Woods, S. C., & Seeley, R. J. (2009) · Regulatory Peptides · doi:10.1016/j.regpep.2009.03.002 · Cited by 37
“In the studies of the role of hepatic portal GLP-1 receptors in glucose homeostasis, blockade of GLP-1 receptors was more effective than administration of GLP-1 in demonstrating effects [5,20].”
InfluentialSelf-citationGlucagon‐Like Peptide‐1: Actions and Influence on Pancreatic Hormone Function
Davis, E., & Sandoval, D. A. (2020) · Comprehensive physiology · doi:10.1002/cphy.c190025 · Cited by 59
“GLP-1 activates vagal afferent neuronal activity and administration of GLP-1r antagonists into the portal vein impairs glucose tolerance (234) suggesting that the peripheral nervous system is also important in mediating GLP-1 effects on glucose homeostasis.”
Kedees, M. H., Guz, Y., Grigoryan, M., & Teitelman, G. (2013) · Peptides · doi:10.1016/j.peptides.2013.07.022 · Cited by 40
Exenatide can reduce glucose independent of islet hormones or gastric emptying
Ionut, V., Zheng, D., Stefanovski, D., & Bergman, R. N. (2008) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.90222.2008 · Cited by 35
Vagal sensory pathway for the gut-brain communication
Cao, Y., Li, R., & Bai, L. (2023) · Seminars in Cell and Developmental Biology · doi:10.1016/j.semcdb.2023.07.009 · Cited by 41
Gong, N., Li, X., Xiao, Q., & Wang, Y. (2013) · Anesthesiology · doi:10.1097/aln.0b013e3182a66d2a · Cited by 35
Røder, M. E. (2017) · Therapeutic Advances in Chronic Disease · doi:10.1177/2040622317735283 · Cited by 39
Dotson, C. D., Vigues, S., Steinle, N., & Munger, S. D. (2010) · PubMed · Cited by 42
Metabolic effects of portal vein sensing
Mithieux, G. (2014) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.12338 · Cited by 34
“Accordingly, the improvement of glucose control by GLP-1 is attenuated upon antagonizing the GLP-1 receptor in the portal vein [6].”
BackgroundWhen GLP-1 hits the liver: a novel approach for insulin resistance and NASH
Kim, Y. O., & Schuppan, D. (2012) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.00078.2012 · Cited by 34
Neuroimmune modulation in liver pathophysiology
Zou, J., Li, J., Wang, X., Tang, D., & Chen, R. (2024) · Journal of Neuroinflammation · doi:10.1186/s12974-024-03181-w · Cited by 43
“Activation of GLP-1 receptors stimulates hepatic vagal afferent nerves, leading to changes in pancreatic insulin release through efferent sympathetic nerve signals originating in the brain [92, 93].”
BackgroundMa, J., Checklin, H. L., Wishart, J. M., Stevens, J. E., Jones, K. L., Horowitz, M., Meyer, J. H., & Rayner, C. K. (2013) · Diabetologia · doi:10.1007/s00125-013-2876-2 · Cited by 36
“Vagal afferents with nerve endings bearing receptors for GLP-1 are present in the portal venous system [32], and activation of these results in glucose lowering through enhanced hepatic and peripheral glucose uptake [33], in the absence of any stimulation of insulin secretion [34, 35].”
BackgroundThe vagus neurometabolic interface and clinical disease
Battinelli, E., Valdés‐Ferrer, S. I., & Steinberg, B. E. (2018) · International Journal of Obesity · doi:10.1038/s41366-018-0086-1 · Cited by 36
Bitarafan, V., Fitzgerald, P. C. E., Little, T. J., Meyerhof, W., Jones, K. L., Wu, T., Horowitz, M., & Feinle‐Bisset, C. (2019) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00294.2019 · Cited by 34
“enhance hepatic and peripheral glucose uptake (41) may also be a”
BackgroundEdgerton, D. S., Johnson, K. M. S., Neal, D. W., Scott, M., Hobbs, C. H., Zhang, X., Duttaroy, A., & Cherrington, A. D. (2009) · Diabetes · doi:10.2337/db08-0515 · Cited by 33
“The GLP-1 receptor has been identified in the hepatic portal vein (47) and the liver (48,49) and could exert its effect through binding at either site, although it appears that portal receptors may not be necessary for the effect (39).”
BackgroundBoland, B. B., Laker, R. C., O'Brien, S., Sitaula, S., Sermadiras, I., Nielsen, J. C., Barkholt, P., Roostalu, U., Hecksher‐Sørensen, J., Sejthen, S. R., et al. (2021) · Molecular Metabolism · doi:10.1016/j.molmet.2021.101392 · Cited by 43
Visceral afferents — Determinants and modulation of excitability
Beyak, M. J. (2009) · Autonomic Neuroscience · doi:10.1016/j.autneu.2009.07.019 · Cited by 31
“With regard to GLP-1, there is emerging literature pointing to the importance of visceral afferents of the vagus in its satiety and glucose homeostatic effects (Abbott et al., 2005; Vahl et al., 2007), however, the evidence demonstrating GLP-1 activating visceral afferents is still sparse.”
BackgroundTargeting the intestinal L-cell for obesity and type 2 diabetes treatment
Albrechtsen, N. J. W., Kuhre, R. E., Deacon, C. F., & Holst, J. J. (2013) · Expert Review of Endocrinology & Metabolism · doi:10.1586/17446651.2014.862152 · Cited by 34
Glucagon-like peptide-1 (GLP-1) action in the mouse area postrema neurons
Kawatani, M., Yamada, Y., & Kawatani, M. (2018) · Peptides · doi:10.1016/j.peptides.2018.07.010 · Cited by 32
Distribution and Stimulus Secretion Coupling of Enteroendocrine Cells along the Intestinal Tract
Adriaenssens, A. E., Reimann, F., & Gribble, F. M. (2018) · Comprehensive physiology · doi:10.1002/cphy.c170047 · Cited by 41
Mechanistic insights into the liver–brain axis during chronic liver disease
Siddle, M. R., Durán, R. G., Goel, D., Renquist, B. J., Holt, M. K., & Hadjihambi, A. (2025) · Nature Reviews Gastroenterology & Hepatology · doi:10.1038/s41575-025-01142-z · Cited by 41
“73,74), CCK 75,76 , ghrelin 66 , PYY 77 and leptin 78 (Table 1 and Supplementary Table 1).”
InfluentialHao, M., Kuang, H., Fu, Z., Gao, X., Liu, Y., & Deng, W. (2012) · Neurochemistry International · doi:10.1016/j.neuint.2012.04.009 · Cited by 31
Protection of exenatide for retinal ganglion cells with different glucose concentrations
Fu, Z., Kuang, H., Hao, M., Gao, X., Liu, Y., & Shao, N. (2012) · Peptides · doi:10.1016/j.peptides.2012.06.006 · Cited by 32
Foregut exclusion disrupts intestinal glucose sensing and alters portal nutrient and hormonal milieu
Pal, A., Rhoads, D. B., & Tavakkoli, A. (2015) · Diabetes · doi:10.2337/db14-1578 · Cited by 29
“GLP-1 receptor is expressed in the portal vein wall (23).”
BackgroundRebelos, E., Iozzo, P., Guzzardi, M. A., Brunetto, M. R., & Bonino, F. (2021) · World Journal of Gastroenterology · doi:10.3748/wjg.v27.i30.4999 · Cited by 33
Glucagon-like peptide 1 and the brain: Central actions–central sources?
Trapp, S., & Hisadome, K. (2010) · Autonomic Neuroscience · doi:10.1016/j.autneu.2010.09.008 · Cited by 32
“, 2000) and that GLP-1 receptors are expressed on nerve terminals in the portal vein (Vahl et al., 2007).”
BackgroundJessen, L., Aulinger, B. A., Hassel, J. L., Roy, K. J., Smith, E. P., Greer, T. M., Woods, S. C., Seeley, R. J., & D'Alessio, D. A. (2012) · Endocrinology · doi:10.1210/en.2012-1358 · Cited by 29
Self-citationGribble, F. M. (2008) · Diabetic Medicine · doi:10.1111/j.1464-5491.2008.02514.x · Cited by 32
Mechanisms for the cardiovascular effects of glucagon-like peptide-1
Poudyal, H. (2015) · Acta Physiologica · doi:10.1111/apha.12604 · Cited by 34
“…the GLP-1 receptor was detected in rat nodose ganglion, equally left- and right-side ganglia, suggesting an extrahepatic occurrence of vagal GLP-1 reception in addition to the reception through the hepatic vagus, which originates from the left-side ganglion (Nakagawa et al. 2004, Vahl et al. 2007).”
BackgroundGlucagon‐like peptide‐1 drives energy metabolism on the synaptic highway
Liu, J., & Pang, Z. P. (2016) · The FEBS Journal · doi:10.1111/febs.13785 · Cited by 28
D’Alessio, D. A. (2011) · Endocrinology · doi:10.1210/en.2011-1385 · Cited by 27
“Moreover, theGLP-1receptor is present on axons in the portal vein (6), and infusion of GLP-1 or a GLP-1 antagonist limited to the hepatic-portal bed has effects on glucose metabolism (6–9).”
BackgroundSelf-citationExendin(9‐39) NH 2 : Recommendations for clinical use based on a systematic literature review
Gasbjerg, L. S., Bari, E. J., Christensen, M., & Knop, F. K. (2021) · Diabetes Obesity and Metabolism · doi:10.1111/dom.14507 · Cited by 29
Ushiama, S., Ishimaru, Y., Narukawa, M., Yoshioka, M., Kozuka, C., Watanabe, N., Tsunoda, M., Osakabe, N., Asakura, T., Masuzaki, H., et al. (2016) · EBioMedicine · doi:10.1016/j.ebiom.2016.04.031 · Cited by 28
“…on vagal afferent nerve terminals in the portal vein and in the brain across the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/). the blood-brain barrier, which is involved in the regulation of appetite (Katsurada et al., 2014; Kinzig et al., 2002; Vahl et al., 2007).”
BackgroundInfluentialGLP-1-Based Strategies: A Physiological Analysis of Differential Mode of Action
Burcelin, R., Gourdy, P., & Dalle, S. (2014) · Physiology · doi:10.1152/physiol.00009.2013 · Cited by 26
Kuthati, Y., Davuluri, V. N. G., & Wong, C. (2025) · Biomolecules · doi:10.3390/biom15050622 · Cited by 32
“Vahl and colleagues analyzed multiple tissues of Sprague–Dawley rats and reported undetectable expression levels of GLP-1R mRNA in the spinal cord [37].”
Targeting the gastrointestinal tract to treat type 2 diabetes
Bauer, P. V., & Duca, F. A. (2016) · Journal of Endocrinology · doi:10.1530/joe-16-0056 · Cited by 29
“However, GLP-1Rs are also located on neurons innervating the portal vein (Vahl et al. 2007), on β cells”
BackgroundArnes, L., Moreno, P., Nuche‐Berenguer, B., Valverde, I., & Villanueva‐Peñacarrillo, M. L. (2008) · Regulatory Peptides · doi:10.1016/j.regpep.2008.08.005 · Cited by 29
“In fact, the data obtained in the present study shows that Ex-4 treatment increases, up to normalization, the initial lower than normal liver glycogen storage in T2D rats, suggesting a direct effect of Ex-4 upon the liver glucose uptake; nevertheless it must be taken into consideration evidences from a recent report w…”
BackgroundPlamboeck, A., Veedfald, S., Deacon, C. F., Hartmann, B., Vilsbøll, T., Knop, F. K., & Holst, J. J. (2015) · American Journal of Physiology-Regulatory, Integrative and Comparative Physiology · doi:10.1152/ajpregu.00123.2015 · Cited by 25
“However, infusion of glucose and GLP-1 into a peripheral vein, as used here, is not representative of the physiological situation, where high concentrations of endogenous GLP-1 (13, 19) may activate GLP-1Rs on afferent fibers (48).”
BackgroundAmouyal, C., & Andreelli, F. (2016) · Journal of Diabetes Research · doi:10.1155/2016/5908656 · Cited by 25
Gastrointestinal peptides in eating-related disorders
Smith, K., & Moran, T. H. (2021) · Physiology & Behavior · doi:10.1016/j.physbeh.2021.113456 · Cited by 28
The (dys)regulation of energy storage in obesity
Levin, B. E., Geary, N., & Lutz, T. A. (2025) · Physiological Reviews · doi:10.1152/physrev.00002.2024 · Cited by 29
Metadata
- Authors
- Vahl, T. P., Tauchi, M., Durler, T. S., Elfers, E. E., Fernandes, T. M., Bitner, R. D., Ellis, K. S., Woods, S. C., Seeley, R. J., Herman, J. P., & D’Alessio, D. A.
- Affiliations
- University of Cincinnati (US)
- Corresponding author
- D’Alessio, David A.
- ORCID
- Venue
- Endocrinology
- Publisher
- The Endocrine Society
- Published
- 2007-10-01
- Volume
- 148
- Issue
- 10
- Pages
- 4965-4973
- ISSN
- 0013-7227 (ISSN-L)
- 1945-7170
- OpenAlex
- W2128181185
- Cited by
- 318
- References
- 57
- Citations by year
- 2026: 4 · 2025: 8 · 2024: 10 · 2023: 11 · 2022: 9 · 2021: 20 · 2020: 9 · 2019: 11 · 2018: 13 · 2017: 14 · 2016: 21 · 2015: 25 · 2014: 24 · 2013: 32 · 2012: 23
- FWCI
- 13.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- Endocrinology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- University of Cincinnati
- National Institutes of Health (DK17844)
- National Institute of Mental Health (MH 069680)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK 54263, DK17844, R01DK054890, DK-54890, T35DK060444)
- Topics
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Diabetes Treatment and Management
- Life Sciences › Neuroscience › Endocrine and Autonomic Systems › Regulation of Appetite and Obesity
- Health Sciences › Medicine › Endocrinology, Diabetes and Metabolism › Pancreatic function and diabetes
- Keywords
- glucagon-like peptide-1, GLP-1 receptor, glucose tolerance, portal vein, visceral afferent neurons, nodose ganglion, exendin-4, glucose homeostasis, intraportal infusion
- MeSH terms
- Glucagon-Like Peptide-1 Receptor, Exenatide, Animals, Blood Glucose, Cell Line, Dose-Response Relationship, Drug, Glucose, Glucose Tolerance Test, Infusions, Intravenous, Liver, Male, Nerve Endings, Nodose Ganglion, Peptides, Portal Vein, Venoms, Rats, Sprague-Dawley, Receptors, Glucagon, Glucose Intolerance, Rats, Glucagon-Like Peptide 1
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.